Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2026 | FGFR-directed therapy in NMIBC: a step toward precision medicine in bladder cancer

Antoni Vilaseca • 15 Mar 2026
EAU 2026
Bladder Cancer Genitourinary Cancer

Antoni Vilaseca, MD, Hospital Clínic de Barcelona, Barcelona, Spain, discusses the significance of FGFR mutations in non-muscle-invasive bladder cancer (NMIBC), highlighting that approximately 70% of patients with intermediate-risk disease and 40% of those with high-risk NMIBC harbor these alterations. Dr Vilaseca notes that while mutational testing is not currently routine in NMIBC, it is commonly performed in other cancers, including prostate cancer, and emphasizes the need for hospitals and laboratories to adapt to precision medicine approaches that are emerging in the NMIBC setting. This interview took place at the 41st Annual EAU Congress in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Antoni Vilaseca

Intravesical erdafitinib in BCG-unresponsive NMIBC: local efficacy, minimal systemic exposure
1:14
Intravesical erdafitinib in BCG-unresponsive NMIBC: local efficacy, minimal systemic exposure
Antoni Vilaseca • 15 Mar 2026
Phase I study of erda-iDRS, an erdafitinib intravesical drug-releasing system, in FGFRm NMIBC
2:38
Phase I study of erda-iDRS, an erdafitinib intravesical drug-releasing system, in FGFRm NMIBC
Antoni Vilaseca • 15 Mar 2026
The future of the TAR-210 delivery system for erdafitinib in NMBIC
0:56
The future of the TAR-210 delivery system for erdafitinib in NMBIC
Antoni Vilaseca • 21 Oct 2023
TAR-210 erdafitinib intravesical delivery system in non-muscle invasive bladder cancer
2:15
TAR-210 erdafitinib intravesical delivery system in non-muscle invasive bladder cancer
Antoni Vilaseca • 21 Oct 2023

Related Videos

How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals